On August 18, 2015, FDA approved flibanserin (Addyi; Sprout Pharmaceuticals) for the treatment of premenopausal women experiencing distress resulting from acquired generalized hypoactive sexual desire disorder (HSDD) not caused by a medical or psychiatric condition, relationship problems, or the effects of medications or other substances.
In October 2015, the manufacturer made the drug available by for prescribing and appropriate use. Because of concerns about adverse effects, training through the Addyi REMS program is required for prescribers and pharmacies that want to participate in the medication use process for this drug. Prescribers must also complete the Addyi REMS provider-patient agreement form with each patient before prescribing Addyi.
Flibanserin is a 5-HT1A receptor agonist and a 5-HT2A receptor antagonist: As such, through unknown mechanisms it affects pleasure pathways of the brain and affects a woman’s sense of sexual desire.
The drug’s efficacy, which led to its FDA approval, was based primarily on three 24-week, randomized, double-blind, placebo-controlled clinical trials. Participants in these trials were premenopausal women experiencing significant distress or relationship difficulties due to acquired, generalized HSDD for at least six months and who previously had no concerns with sexual desire.
Participants received either 100 mg flibanserin (1,227 participants) at bedtime or placebo (1,238 participants). Change in monthly satisfying sexual events (SSEs) from baseline to week 24 and in sexual desire as calculated by participant diary responses (studies 1 and 2) or the Female Sexual Function Index (FSFI) (study 3) served as co-primary endpoints in the studies. The FSFI was assessed as a secondary endpoint in studies 1 and 2. All three trials assessed the degree of bother, an aspect of distress, experienced in relation to low sexual desire as a secondary endpoint.
Participants taking flibanserin had an average increase of 0.5 to 1.0 SSE per month compared to participants taking placebo. Measures of distress demonstrated that participants taking flibanserin “frequently” to “always” experienced distress related to low desire at baseline; by week 24, they experienced distress “occasionally” to “frequently.”
Flibanserin is not indicated for treatment of HSDD in postmenopausal women, for use in men, or for enhancement of sexual performance. Addyi carries a boxed warning citing severe hypotension and syncope, particularly when used by patients with hepatic impairment or when taken in combination with alcohol, moderate to strong CYP3A4 inhibitors, or certain herbal supplements. Flibanserin use is contraindicated in these circumstances.
Certified pharmacies may dispense flibanserin only pursuant to a prescription from a certified prescriber. Every patient must be counseled to abstain from alcohol during treatment with flibanserin to avoid the increased risk of syncope associated with concomitant use. In trials, the most common adverse effects associated with flibanserin included dizziness, nausea, tiredness, difficulty sleeping, and dry mouth.
A simulated driving impairment and cognition study was performed to evaluate the residual effects of bedtime flibanserin dosing on awakening the next day. In these tests, flibanserin demonstrated effects similar to placebo after seven hours of sleep. In light of these results, it might be prudent to counsel patients not to drive or perform tasks requiring attention within seven hours of taking flibanserin — at least until the patient knows how she will react to the medication.